Clinical Trials

    A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1

    Investigator: Ericka Greene

    Study Coordinator: Aramide Balogun

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT06411288

    Phone: 713.441.6955

    Protocol Number: PRO00040132

    Description


    A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1